8-KEarnings & ResultsExhibits & Filings

BIOGEN INC. 8-K Report, Financial Results (Apr 24, 2018)

Filed April 24, 2018For Securities:BIIB

Summary

Biogen Inc. (BIIB) filed an 8-K on April 24, 2018, primarily to announce its first-quarter 2018 financial results via a press release. This filing serves as a notification to investors regarding the company's performance for the period ending March 31, 2018. The key details of these results are found within the furnished press release (Exhibit 99.1), which is crucial for understanding Biogen's operational and financial standing at that time. While the 8-K itself does not contain the detailed financial figures, it directs investors to the press release for comprehensive information. Investors should review Exhibit 99.1 to assess revenue, profitability, earnings per share, and any forward-looking guidance provided by Biogen for the quarter. The filing is furnished and not deemed 'filed' for certain regulatory purposes, meaning it's a disclosure of information rather than a definitive filing subject to specific liabilities.

Key Highlights

  • 1Biogen Inc. announced its first-quarter 2018 financial results on April 24, 2018.
  • 2The company's results were disclosed via a press release, furnished as Exhibit 99.1 to the 8-K.
  • 3Investors are directed to the press release for specific details on operations and financial condition for the quarter ended March 31, 2018.
  • 4The filing's purpose is to inform investors of the quarterly performance.
  • 5The press release is furnished, not filed, under specific sections of the Securities Exchange Act of 1934.

Frequently Asked Questions

The specific financial results are detailed in the press release issued by Biogen Inc. on April 24, 2018, which is furnished as Exhibit 99.1 to this Form 8-K filing. Investors should refer to that document for precise figures.

When information is 'furnished' under Item 2.02 of an 8-K, it means the company is providing the information to the SEC and the public, but it is not subject to the same liabilities and regulatory scrutiny as information that is formally 'filed' with the SEC, such as under Section 18 of the Exchange Act. This is a common practice for earnings releases.

This 8-K filing itself does not provide guidance. However, the accompanying press release (Exhibit 99.1) may contain forward-looking statements and guidance from Biogen regarding its future financial performance and business outlook. Investors should review the press release to ascertain if such information was provided.